The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
News|Articles|December 18, 2013
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-01-08-2014
- Volume 10
- Issue 1
Bridgepoint Development Capital Acquires Quotient Clinical
Author(s)Pharmaceutical Technology Editors
Bridgepoint Development Capital acquires Quotient for an undisclosed sum.
Advertisement
Quotient Clinical, a provider of outsourced, early-stage drug development services to the pharmaceutical industry, has been acquired from the Quotient Bioresearch Group by
Quotient Clinical is currently part of Quotient Group, which is disposing of the business and represents a primary management buyout. The transaction is subject to standard regulatory clearances.
Source:
Articles in this issue
over 12 years ago
New Dynamics in Drug Pricing and Prescribingover 12 years ago
Climate Change Drives New Opportunities in Outsourcingover 12 years ago
BMS Grants Support Mental Health Needs of US Military Veteransalmost 13 years ago
Cambrex Completes FDA Inspectionalmost 13 years ago
Metrics Appoints New Vice-Presidentalmost 13 years ago
GDUFA Off to Good Start, But Storm Clouds on the HorizonAdvertisement
Related to this article
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Advertisement
Advertisement